Several single-center studies suggested an improved sensitivity of positron emission tomography (PET) targeting the prostate-specific membran antigen (PSMA) for staging intermediate- to high-risk prostate cancer (PCa) [1–4]. This evidence concerns the gene FOLH1 and prostate cancer.